Tenderwize
Retour à la recherche

Accord de remise non exclusif pour le pegfilgrastim

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Nov 27, 2026 · 6 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Pegfilgrastim (ATC-Code L03AA13).

55/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

55 / 100

Complexité

63 / 100

Facteurs de risque

The contract may end automatically when exclusive discount contracts enter into force, potentially before 31 January 20...

No guaranteed volume, expenditure, or estimated value is stated, so the commercial opportunity cannot be quantified fro...

Submission deadline in 6 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Niedersachsen. Die Gesundheitskasse.
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Nov 27, 2026

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2027
  • Conclusion of a non-exclusive medicinal-product discount agreement for Pegfilgrastim, ATC code L03AA13.
  • Coverage relates to performance in Germany, specifically the AOK Niedersachsen area identified by subdivision code DE929.
Afficher le résumé complet

AOK Niedersachsen intends to conclude a non-exclusive open-house discount agreement for medicinal products containing Pegfilgrastim (ATC L03AA13) in Germany. Eligible pharmaceutical entrepreneurs or qualifying groups may join on identical, non-negotiable terms without a selection decision. The agreement may run until 31 January 2027 but can end earlier if exclusive contracts enter into force. Contract documents must be requested from the buyer; no procurement documents or submission forms were provided for analysis.

Risques

The contract may end automatically when exclusive discount contracts enter into force, potentially before 31 January 20...

No guaranteed volume, expenditure, or estimated value is stated, so the commercial opportunity cannot be quantified fro...

Submission deadline in 6 days

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The participant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the offered medicinal products, or a group of such pharmaceutical entrepreneurs.
  • A pharmaceutical entrepreneur placing medicinal products on the market in the AMG area must have its seat in Germany, another EU Member State, or another EEA contracting state.
  • A local representative may participate only if it is itself a pharmaceutical entrepreneur for the relevant medicinal products.

Critères d'attribution

Lot 1

Price is identified as the award criterion, but no description or numeric weighting is provided. The open-house model states that no selection decision is made.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Pegfilgrastim non-exclusive discount agreement

Non-exclusive discount agreement under Section 130a(8) SGB V for medicinal products containing Pegfilgrastim, ATC L03AA13, under an open-house model. The buyer intends to offer identical terms to all interested eligible pharmaceutical entrepreneurs or groups, with no selection decision or individual negotiations. Contracts may be concluded during the term, subject to monthly commencement dates and the stated lead time.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Jan 2025 - Jan 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Nov 27, 2026

Détails de la procédure

Date de publication
08 Dec 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
750560-2024

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy